The South San Francisco, California-based single-cell biology firm brought in $25.5 million compared to $29.0 million in the first quarter of 2016.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.
The method allows analysis of copy number at the individual cell level with greater coverage uniformity and more reliable detection than other approaches.
Sales of Helios instruments and genomics analytical consumables were lower than expected, pulling down revenues.
The researchers will use single-cell genomics and other approaches to generate information that could ultimately be used to diagnose, monitor, and treat disease.
The planned solution will enable secondary and tertiary analysis and visualization of single-cell sequence data.
Bio-Techne has also agreed to pay up to an additional $75 million if Advanced Cell Diagnostics achieves certain milestones.
The Food Allergy Science Initiative seeks to supply the basic scientific research needed to spur future development of diagnostics and therapeutics.
In Genome Biology this week: signaling in ovarian tumor microenvironment, neuronal aneuploidy in Alzheimer's disease, and more.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.